Skip to main content

Table 4 Relationship between plasma levels of IL-27 and patients’ characteristics

From: Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer

Variable analyzed

 

IL-27 (pg/ml)

 

Total, N

Mean

SD

SEM

Median

P

Case–control

      

 Controls

151

38.21

28.76

2.56

37.80

< 0.0001

 NMIBC

74

21.16

21.92

2.91

13.91

 MIBC

50

27.34

32.87

5.72

18.41

Agea

      

 ≤65

88

26.49

32.23

4.8

16.33

0.94

 >65

36

20.36

18.91

2.82

15.29

Sex

      

 Male

96

24.13

27.14

3.22

16.33

0.43

 Female

28

20.81

24.20

5.55

15.04

Smoking status

      

 Smokers

73

22.86

25.80

3.42

16.33

0.55

 Non-smokers

51

24.40

27.93

4.86

13.61

Tumor grade

      

 Low grade

53

18.63

19.36

2.99

12.99

0.058

 High grade

71

27.62

30.97

4.47

17.85

rs153109

      

 AA

41

20.99

18.68

3.47

15.66

0.69

 AG

61

26.07

31.37

4.44

15.69

 GG

22

17.80

18.45

5.56

13.51

rs17855750

      

 TT

101

25.11

28.21

3.35

15.66

0.055

 TG

20

17.13

17.64

4.05

10.93

 GG b

3

-

-

-

-

  1. N corresponds to the number of individuals
  2. aThe threshold for age is based on median of bladder cancer patients
  3. bPlasma IL-27 levels for all of these 3 samples were under the detection threshold for the present ELISA kits and their value was conservative determined as 5.9 pg/mL, which is the minimum detectable dose of IL-27 for the kits used in the present study
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us